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Abstract
Background: Poly(ADP-ribose) is a NAD
+-requiring, DNA-repairing, enzyme playing a central role in pancreatic
b-cell death and in the development of endothelial dysfunction in humans and experimental animals. PARP
activation is also relevant to the development of complications of diabetes. Hence, agents capable of inhibiting
PARP may be useful in preventing the development of diabetes and in slowing down complications of diabetes.
Methods: PARP inhibition was assessed with a colorimetric assay kit. Molecular docking studies on the active site of
PARP were conducted using the crystalline structure of the enzyme available as Protein Data Bank Identification No.
1UK1. Type 2 diabetes was induced in male Sprague-Dawley rats with streptozotocin (STZ, 60 mg/kg, i.p.). The test
compounds (3-aminobenzamide = 3-AB, nicotinamide = NIC, taurine = TAU) were given by the i.p. route 45 min before
STZ at 2.4 mM/kg (all three compounds) or 1.2 and 3.6 mM/kg (only NIC and TAU). Blood samples were collected at
24 hr after STZ and processed for their plasma. The plasma samples were used to measure glucose, insulin, cholesterol,
triglycerides, malondialdehyde, nitric oxide, and glutathione levels using reported methods.
Results: 3-AB, NIC and TAU were able to inhibit PARP, with the inhibitory potency order being 3-AB>NIC>>TAU.
Molecular docking studies at the active site of PARP showed 3-AB and NIC to interact with the binding site for the
nicotinamide moiety of NAD
+ and TAU to interact with the binding site for the adenine moiety of NAD
+. While
STZ-induced diabetes elevated all the experimental parameters examined and lowered the insulin output, a
pretreatment with 3-AB, NIC or TAU reversed these trends to a significant extent. At a dose of 2.4 mm/kg, the
protective effect decreased in the approximate order 3-AB>NIC≥TAU. The attenuating actions of both NIC and TAU
were dose-related except for the plasma lipids since NIC was without a significant effect at all doses tested.
Conclusions: At equal molar doses, 3-AB was generally more potent than either TAU or NIC as an
antidiabetogenic agent, but the differences were not as dramatic as would have been predicted from their
differences in PARP inhibitory potencies. NIC and TAU demonstrated dose-related effects, which in the case of TAU
were only evident at doses ≥2.4 mM/kg. The present results also suggest that in the case of NIC and TAU an
increase in dose will enhance the magnitude of their attenuating actions on diabetes-related biochemical
alterations to that achieved with a stronger PARP inhibitor such as 3-AB. Hence, dosing will play a critical role in
clinical studies assessing the merits of NIC and TAU as diabetes-preventing agents.
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Poly(ADP-ribose) polymerases (PARPs) are of group of
at least 18 different cell signaling enzymes that catalyze
the transfer of ADP-ribose units from NAD
+ to a num-
ber of acceptor molecules [1]. Among PARPs, PARP-1
has attracted a great deal of attention because of its
relevance to the development of type 1 diabetes and its
complications. This chromatin-bound nuclear enzyme is
activated upon DNA injury as a result of genotoxic
stress by oxidants, oxygen-derived free radicals and
nitric oxide (NO) and, upon binding to single-strand
DNA breaks it recruits a ligase complex to carry out
base excision repair and, at the same time, it cleaves
nicotinamide adenine dinucleotide (NAD
+)i n t on i c o t i -
namide and ADP-ribose residues which are covalently
attached to nuclear and extranuclear (e.g. mitochondrial)
proteins to form poly(ADP-ribose) [2-5]. Continuous
PARP activity in the pancreas leads to large amounts of
the (ADP-ribose) polymer, the depletion of NAD
+ to
nonphysiological levels, a decrease in protein synthesis,
inhibition of insulin synthesis, and necrotic b-cell death
[6-8]. Overactivity of PARP is also associated with ATP
depletion because of increased use to regenerate NAD
+
from nicotinamide, impaired mitochondrial function and
a slow rate of glycolysis [3,5,9]. When ATP levels
decrease below a critical threshold following proapopto-
tic insults, necrotic cell death ensues [3,10].
PARP inhibitors have the ability to prevent intracellu-
lar NAD
+ consumption and decreases of the ATP pool,
and to protect pancreatic b-cells from chemically
induced necrosis but not from cytokine-mediated apop-
tosis, a major cause of autoimmune diabetes [11].
Furthermore, PARP inhibition has been found to not
only prevent but also reverse aortic endothelial dysfunc-
tion in animals made diabetic through pharmacological
intervention. At the same time, PARP inhibition was
able to reverse the losses of endothelial ATP, NAD
+ and
NADPH caused by diabetes [11]. Because of the world-
wide rise in the incidence of diabetes mellitus and the
epidemic proportions reached by this endocrine disor-
der, compounds classified as PARP inhibitors are conti-
nually being tested for preventing the development of
diabetes and its complications and for reversing dia-
betes-related organ and nerve dysfunction [11-13]. How-
ever, since complete inhibition of PARP will deprive
cells from the benefits of DNA repair during periods of
oxidative stress, thus contributing to cytotoxicity [14],
studies on highly potent first generation PARP inhibitors
like 3-aminobenzamide (3-AB) has been limited to
laboratory animals. Another beneficial effect of PARP
inhibitors like 3-AB, in addition to preventing pancreatic
d a m a g eb yad i a b e t o g e n i ca g e n t ,i st op r e s e r v et h ea b i l -
ity of the pancreas to secrete insulin in response to
hyperglycemia [15]. In contrast, nicotinamide (NIC), a
weaker first-generation PARP inhibitor and a precursor
of NAD
+, has been the subject of intensive clinical trials
around the world as a means of preventing or delaying
the clinical onset of diabetes in humans [12,16-18]. In
addition, this water-soluble form of vitamin B3 possesses
other properties that may be of benefit in diabetes such
as antioxidant action, modulatory role on neuronal Ca
++
influx, inhibitory action on apoptosis [5], and ability to
preserve residual b-cell function, enhance b-cell regen-
eration, and promote islet cell growth [18].
Among natural compounds, taurine (TAU) is among
those most extensively investigated for its attenuating
effects on diabetes-related alterations such as decreased
insulin secretion [19,20], hyperglycemia [19,21] hyperli-
pidemia [21,22], lipid peroxidation (LPO) [21-23], and
formation of advanced protein glycation products [23]
in animal models of spontaneous and pharmacologi-
cally-induced diabetes. By analogy to 3-AB and NIC, in
nonobese diabetic (NOD) mice TAU was found to pro-
mote islet cell proliferation, lower the incidence of pan-
creatic apoptosis, reduce islet cell insulitis and delay the
onset of diabetes when consumed as a diet supplement
early in life [24].
In view of the similarity of protective actions mani-
fested by TAU, 3-AB and NIC against diabetes it
appeared of interest to determine whether or not TAU
is endowed with PARP-inhibiting action and, if this is
the case, to what extent differences in PARP-inhibiting
potency among TAU, 3-AB and NIC impact on the
extent of their antidiabetic effects. To attain these goals,
TAU, 3-AB and NIC were tested both in vitro for
PARP-1 inhibiting power and for mode of interaction
with the active site of PARP-1 in rats and in vivo, using
rats made diabetic with streptozotocin, (STZ), a known
generator of oxygen and nitrogen reactive species, for
their counteracting actions on hypoinsulinemia, hyper-
glycemia, hyperlipidemia and oxidative stress when
administered in equimolar doses as a pretreatment to
STZ. To our knowledge these comparisons have not
been previously reported.
Methods
Animals
All the experiments were carried on male Sprague-Daw-
ley rats, 200-225 g in weight, purchased from Taconic
Farms, Germantown, New York, USA, and housed in a
temperature controlled room (21±1°C) with a 12 hr
light-12 hr dark cycle. The animals were allowed free
access to a standard rat chow and filtered tap water for
at least 5 days. The solid food, but not the water, was
removed 12 hr prior to an experiment. The experimen-
tal groups consisted of 6 animals each. The study
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and Use Committee of St. John’s University, and the
animals were cared in accordance with the guidelines
established by the United States Department of
Agriculture.
Treatments and samples
Solutions of STZ, 3-AB, NIC and TAU were made in
citrate buffer pH 4.6, and they were administered by the
intraperitoneal (i.p.) route in a volume not exceeding
2 ml. The doses used were: STZ 60 mg/kg, 3-AB 2.4
mM/kg, TAU 1.2-3.6 mM/kg, NIC 1.2-3.6 mM/kg. 3-AB
and NIC were administered 45 min before STZ. TAU
was administered in divided doses, one-half at 75 min
before STZ and one-half at 45 min before STZ. Control
animals received only citrate buffer pH 4.6 in a volume
equal to that of a treatment solution. All the animals
were decapitated at 24 hr after a treatment with STZ,
and their blood samples, collected into heparinized
tubes, were processed for their plasma fractions.
PARP inhibitory action
The inhibitory action of the test compounds towards
PARP-1 was determined using a commercially available
microplate assay kit (Universal Colorimetric PARP
Assay from Trevigen, Inc., Gaithersburg, MD) and in
accordance with the instructions provided by the manu-
facturer. Stock solutions of the various test compounds
were made in dimethyl sufoxide, which were then seri-
ally diluted to the required concentration (100 µM) with
distilled water. For the assay, each strip well was filled
with 10 µL of the inhibitor solution, 15 μLo fd i l u t e d
PARP-1 enzyme (providing 0.5 Unit/well), and 25 µL of
PARP Cocktail (consisting of biotinylated NAD, acti-
vated DNA in Tris-Cl pH 8.0, and EDTA). The strip
wells were incubated at room temperature for 60 min,
and then washed 4 times with phosphate buffered saline
(PBS: Na2HPO4,N a H 2PO4,a n dN a C l )a n d0 . 1 %T r i t o n
X-100. Then, 50 µL of diluted Strep-HRP (blocking
solution) was added to each well, and the strips were
further incubated at room temperature for 60 min. After
washing the wells 4 times each with PBS and with 0.1%
Triton X-100, they were mixed with 50 µL of TACS-
Sapphire™ colorimetric substrate, and allowed to stand
in the dark for 10-15 min. The intensity of the blue
color that developed in each well was read on a micro-
plate reader set at 630 nm. After stopping the reaction
by adding 50 µL of 5% phosphoric acid to each well, the
absorbance of the yellow color was measured at 450
nm. Parallel experiments were conducted by substituting
the test solution with an equivalent volume of dimethyl
sulfoxide or distilled water to verify the effect of the
vehicles on the enzyme activity. All the samples were
tested in triplicate.
To determine the IC50 value for the inhibitors, the
compounds were further tested using 5 different con-
centrations ranging from 5 µM to 500 µM and the aver-
age absorbance of each inhibitor concentration was
plotted against the log of the concentration of inhibitor
producing each absorbance value (semi-log plot) and
the IC50 value for each plot was obtained using Regres-
sion Wizard from Sigma Plot version 10.0 (Systat, San
Jose, CA). All the assays were conducted in two separate
occasions, each time in triplicate. The results of these
studies are presented as mean ± standard deviation (SD)
and are reported in μM.
Molecular modeling studies
Molecular docking computations were carried out on a
Dell Precision 470n workstation with the RHEL 4.0
operating system using Glide 5.0. 3D Structures of the
various test compounds were constructed using the
fragment dictionary of Maestro 9.0. The geometry of
the ligands was optimized by Macromodel program
v9.5 using the Optimized Potentials for Liquid Simula-
tions-all atom (OPLS-AA) force field [25] with the
steepest descent followed by truncated Newton conju-
gate gradient protocol. The X-ray crystallographic
structure of PARP-1 in complex with quinazolinedione,
a PARP inhibitor (PDB ID: 1UK1) [26], obtained from
the RCSB Protein Data Bank (PDB),was used to model
the protein structure in this study. The protein was
optimized for docking using the “Protein Preparation
Wizard” and “Prime-Refinement Utility” of Maestro
9.0. The inhibitors were glide docked into the PARP-1
a c t i v es i t eb yt h ee x t r ap r e c i s i o nG l i d ed o c k i n gm e t h o d
and upon completion of each docking calculation, 100
poses at most per ligand were allowed to generate.
Identical binding poses with better Glidescore of each
of the target compounds (where a lower value reflects
a stronger binding than a higher one) were selected for
use in determining the residues on the PARP active
site participating in the binding to the ligands under
evaluation.
Assay of plasma glucose
The content of glucose in a plasma sample was mea-
sured using a commercially available colorimetric assay
kit (Procedure No. 510, Sigma Chemical Co., St. Louis,
MO) which is based on the method of Rabbo and Ter-
kildsen [27]. In the assay, an aliquot of plasma sample is
mixed with an enzyme-color reagent solution consisting
of glucose oxidase, peroxidase, and ortho-dianisidine,
and the reaction is allowed to proceed at 37°C for
30 min. The absorbance of the colored solution is read
on a spectrophotometer at 450 nm. The concentration of
glucose in the sample was calculated by reference to a
glucose standard solution provided by the manufacturer
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The result was expressed in mg/dl of plasma.
Assay of plasma insulin
The quantity of insulin released into the plasma was
measured using a commercially available solid phase
two-site Insulin ELISA immunoassay kit and strips
coated with insulin MAb (Catalog No. IS130D, Calbio-
tech, Inc., Spring Valley, CA). This assay is based on a
direct sandwich technique in which two monoclonal
antibodies (enzyme (HRP)-conjugated anti-insulin and
anti-insulin antibody bound to a microtitration well) are
directed against separate antigenic determinants on the
insulin molecule. Following a washing step to remove
any unbound enzyme labeled antibody, the bound HRP
complex is detected by reaction with TMB to yield a
colored product that can be read on an ELISA plate
reader. The results were expressed as μIU/ml.
Assay of plasma total cholesterol
The concentration of total cholesterol in a plasma sam-
ple was measured using a commercially available enzy-
matic-colorimetric assay kit (Liquizyme® Cholesterol,
Beacon Diagnostics Pvt. Ltd., Navsari, India). In the
assay, 10 μl of plasma sample was mixed with 1.0 ml of
enzyme-color reagent solution (consisting of cholesterol
esterase, cholesterol oxidase, peroxidase, phenol and 4-
aminoantipyrine), incubated at 37°C for 5 min, and the
absorbance of the solution was read on a spectrophot-
ometer at 505 nm against a blank preparation (the
enzyme-color solution). A standard preparation of cho-
lesterol, treated in identical manner as the plasma sam-
p l e ,w a sa n a l y z e da l o n g s i d ea n du s e da sar e f e r e n c ef o r
calculating the plasma cholesterol content, in mg/dl.
Assay of plasma triglycerides
The concentration of triglycerides in a plasma sample
was measured using a commercially available enzymatic-
colorimetric assay kit (Liquizyme® Triglycerides, Beacon
Diagnostics Pvt. Ltd., Navsari, India). In the assay, 10 μl
of plasma sample was mixed with 1.0 ml of enzyme-
color reagent solution (consisting of lipase, glycerol
kinase, Mg
++, glycerol phosphate oxidase, and peroxi-
dase), incubated at 37°C for 5 min, and the absorbance
of the solution was read on a spectrophotometer at 500
nm against a blank preparation (the enzyme-color solu-
tion). A standard preparation of triglyceride, treated in
identical manner as the plasma sample, was analyzed
alongside and used as a reference for calculating the
plasma triglyceride content, in mg/dl.
Assay of plasma malondialdehyde
The formation of malondialdehyde (MDA) in the plasma
was measured as TBARS by the method of Buege and
Aust [28]. In the assay, 100 μl of plasma sample was
mixed with 900 μl of a TCA-TBA-HCl reagent (contain-
ing 15% TCA, 0.375% TBA and 0.25 N HCl in distilled
water). After incubation at 95°C for 60 min, cooling to
room temperature, and centrifugation at 1000 x g for
10 min, the absorbance of the clear solution was read on
a spectrophotometer at 535 nm against a blank prepara-
tion (the TCA-TBA-HCl reagent solution). The concen-
tration of MDA in the plasma sample was calculated by
reference to a calibration curve prepared from serial dilu-
tions of a stock solution of TEP, treated in identical man-
ner as the plasma sample, and was expressed in nM/ml.
Assay of plasma GSH
The content of GSH in a plasma sample was measured
using the method of Ellman [29] and in which this thiol
compound is reacted with DTNB to form a colored pro-
duct that is measured on a spectrophotometer. In the
assay, a 100 μl aliquot of plasma sample was mixed with
an equal volume of 5% metaphosphoric acid, and the
mixture centrifuged at 2000 rpm for 5 min. A 100 μl por-
tion of the supernatant was mixed with 1.9 ml of 0.1 M
phosphate buffer pH 8.0 and 20 μlo f0 . 0 2MD T N B ,a n d
the absorbance of the solution was read on a spectro-
photometer at 412 nm against a blank preparation (pre-
pared in identical manner as the plasma sample but
lacking the plasma). The concentration of GSH in the
plasma sample was calculated by reference to a calibra-
tion curve for GSH prepared from serial dilutions of a
GSH stock solution that were treated identical manner as
the plasma sample. The result was expressed as μM/ml.
Assay of nitrite
E v i d e n c eo ft h ef o r m a t i o no fN Oi nt h ep l a s m aw a s
obtained indirectly by measuring the content of nitrite by
the method of Kauser et al. [30] which is based on the
use of the Griess reagent. In the assay, a 100 μl aliquot of
plasma sample was mixed with 100 μl of 5% metapho-
sphoric acid, and centrifuged at 2000 rpm for 5 min. A
100 μl aliquot of the supernatant was mixed with 100 μl
of Griess reagent (containing 0.1% NED 2HCl and 1%
sulfanilamide in 5% phosphoric acid), and the absorbance
of the solution was read on a spectrophotometer at 546
nm against a blank preparation (prepared in identical
manner as the plasma sample but lacking the plasma).
The concentration of nitrite in the sample was calculated
by reference to a calibration curve prepared from serial
dilutions of a stock solution of sodium nitrite that were
treated in identical manner as the plasma sample. The
result was expressed in nM/ml.
Statistical analysis of the data
Results are expressed as the mean ± SEM for n = 6.
Intergroup comparisons were carried out by Student’s
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test. Differences were considered to be significant when
p was <0.05.
Results
PARP-1 inhibitory action
3-AB, NIC and TAU were tested for their ability to inhi-
bit PARP-1 using a colorimetric assay kit. The results of
this test indicated that a wide difference in inhibitory
potency existed among these compounds. In terms of
their mean ± SD IC50 values, 3-AB (33 ± 1.8 μM) was
about 6.4-fold more potent than NIC (210 ± 2.9 μM)
and about 9.7-fold more potent than TAU (320 ±
3.4 μM).
Molecular docking experiments on the active site of
PARP-1
PARP-1 is a polypeptide whose activation requires bind-
ing as a homodimeric protein to a nicked DNA. This
polypeptide possesses a highly conserved organization
consisting of three main domains: a N-terminal DNA-
binding domain which acts a DNA nick sensor, a central
portion designated as the automodification domain
(AMD) and which contain regions for dimerization and
for modulating interactions with DNA and with pro-
teins, and a C-terminal region, representing the most
conserved part of the enzyme, and capable of catalyzing
poly(ADP-ribose) synthesis and of binding to target pro-
teins [31]. In turn, this active site, also known as cat
PARP, can be divided into an acceptor (adenosine) site
and a donor (NIC) site. The acceptor site is occupied by
the ADP moiety of poly(ADP-ribose) and the donor by
NAD
+. In the donor site, three subsites are described: a
NIC-ribose (NI) binding site, a phosphate (PH) binding
site and an adenine-ribose (AD) site [31]. To be able to
shed some light on the molecular mechanism of action
of these inhibitors, we performed docking studies of
these three inhibitors at the active site of PARP-1. As
shown in Figures 1, 2, 3, molecular docking of 3-AB
(Figure 1), NIC (Figure 2) and TAU (Figure 3) on the
active site of PARP-1 reveals that while the amide group
of 3-AB and NIC are seen hydrogen bonding to the
hydroxyl group of Ser
904 and amino and carbonyl
groups of the backbone of Gly
863 at the NI binding site
of PARP-1, the highly polar TAU entered into hydrogen
bonding at the AD site with the carbonyl group on the
backbone of Asp
766 and the carboxyl group of Asp
770
via its b-amino group and to the carbonyl and amino
groups on the backbone of Arg
878 via its sulfonic acid
group. Assessment of ligand binding efficiency based on
docking scores indicated a good correlation with the
PARP-1 inhibitory actions of the test compounds (-8.38
for 3-AB; -7.40 for NIC; -4.30 for TAU).
Effects of STZ and treatment compounds on the plasma
glucose and insulin levels
From the data presented in Figure 4A it can be seen
that while STZ caused a massive increase in plasma
Figure 1 Glide-predicted binding pose for 3-AB within the active site of PARP-1. The inhibitor is shown in ball and stick model while the
active site amino acids are shown in stick model. The yellow dotted lines indicate probable H-bonds between the inhibitor and the active-site
amino acids. Amino acids participating in the H-bonding are shown in yellow.
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with 2.4 mM/kg of 3-AB was able to attenuate this
increase significantly (only 45% increase, p<0.001 vs.
STZ) and to a greater extent than that byn equimolar
dose of either NIC (~98% increase, p<0.001 vs. STZ)
or TAU (106% increase, p<0.001 vs. STZ). At a dose of
1.2 mM/kg, NIC was more effective than TAU
(increases equal to 117% and 282% above control,
respectively; with p<0.01 and p<0.001 vs. STZ, respec-
tively), but when the dose of both compounds was
Figure 2 Glide-predicted binding pose for NIC within the active site of PARP-1. The inhibitor is shown in ball and stick model while the
active site amino acids are shown in stick model. The yellow dotted lines indicate probable H-bonds between the inhibitor and the active-site
amino acids. Amino acids participating in H-bonding are shown in yellow.
Figure 3 Glide-predicted binding pose for TAU within the active site of PARP-1. The inhibitor is shown in ball and stick model while the
active site amino acids are shown in stick model. The yellow dotted lines indicate probable H-bonds between the inhibitor and the active-site
amino acids. Amino acids participating in H-bonding are shown in yellow.
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plasma glucose was not only equal with each other but
also equal to the action derived from a 2.4 mm/kg
dose of 3-AB.
While a 60 mg/kg i.p. dose of STZ induced type 2 dia-
betes in the rat and suppressed the insulin output by
about 82% of the control value (p<0.001), a pretreatment
with any of the test compounds was able to preserve the
ability of pancreas to secrete insulin following a treat-
ment with STZ (Figure 4B). In parallel with the results
seen for the plasma glucose, at 2.4 mM/kg, 3-AB was
more effective than equimolar doses of either NIC or
TAU (decreases of 21%, p<0.05, 40% p<0.01, and 56%,
p<0.001, respectively). Increasing the dose of TAU and
NIC to 3.6 mM/kg led to protective actions than were
of equal magnitude (only 20% decrease, p<0.05 vs.
Figure 4 Effects of 3-AB, NIC and TAU on plasma (A) glucose and (B) insulin of diabetic rats. Data are presented as mean ± S.E.M. for n =
6. Statistical comparisons were significantly different at **P<0.01 and ***P<0.001 vs. Control; at
++P<0.01 and
+++P<0.001 vs. STZ; and at °P<0.05,
°°P<0.01 and °°°P<0.001 vs. 3-AB.
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pound at 2.4 mM/kg (Figure 4B).
Effects of STZ and treatment compounds on plasma lipids
As shown in Figure 5A, STZ elevated the plasma total
cholesterol by 147% over the control value (p<0.001).
The same Figure also indicates that a pretreatment with
2.4 mM/kg dose of either 3-AB (only 72% increase,
p<0.01 vs. STZ) or TAU (only 76% increase, p<0.01 vs.
STZ) but not one with NIC (123% increase, p<0.001 vs.
control). While at a 1.2 mM/kg dose TAU exerted a
marginal attenuating effect (98% increase, p<0.001 vs.
control), at this dose NIC produced an effect that was
identical to that achieved at twice the dose. Raising the
dose of a treatment compound to 3.6 mM/kg led to a
marked enhancement of the anticholesterolemic action
Figure 5 Effects of 3-AB, NIC and TAU on plasma (A) total cholesterol and (B) triglycerides of diabetic rats. Data are presented as mean
± S.E.M. for n = 6. Statistical comparisons were significantly different at **P<0.01 and ***P<0.001 vs. Control; at
+P<0.05,
++P<0.01 and
+++P<0.001 vs. STZ; and at °P<0.05, °°P<0.01 and °°°P<0.001 vs. 3-AB.
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no effect on the potency of NIC (120% increase,
p<0.001 vs. control).
From the results shown in Figure 5B, it is apparent
that STZ raised the plasma triglyceride level to a signifi-
cant extent relative to the control value (184%, p<0.001).
The same Figure also indicates that a pretreatment with
2.4 mM/kg dose of either 3-AB (only 55% increase,
p<0.001 vs. STZ) or TAU (105% increase, P<0.01 vs.
STZ), but not one with NIC (152% increase) to SZT
was able to attenuate the effect of STZ. Raising the dose
of the pretreatment compound to 3.6 mM/kg enhanced
the attenuating action of TAU (only 62% increase,
p < 0 . 0 0 1v s .S T Z . )b u tn o tt h a to fN I C( 1 5 2 %i n c r e a s e )
on the plasma triglycerides. At 1.2 mM/kg, TAU had a
negligible counteracting effect on the action of STZ on
the plasma triglyceride level (~135% increase).
Effects on indices of oxidative stress
The occurrence of oxidative and nitrosative stress as a
result of STZ-induced diabetes was assessed on the
basis of the plasma MDA (Figure 6), NO (Figure 7) and
GSH (Figure 8) levels. By itself, SZT increased the
plasma levels of MDA (by75%) and of NO (by ~450%)
but lowered that of GSH (by 70%) to a significant extent
(p<0.001 vs. corresponding control values) (Figure 6). A
pretreatment with any of the test compound resulted in
a significant attenuation of the oxidative stress induced
by STZ. Thus, in terms of the MDA levels, although all
the test compounds demonstrated a significant counter-
acting effect on the formation of this end product of
LPO, TAU was the most effective at all doses examined
(6% increase at 1.2 mM/kg, ~15% below control at ≥2.4
mM/kg) levels (Figure 6). Likewise, the attenuating
action of NIC was also dose-related, with the increases
in MDA formation ranging from 2-52% above control.
On the other hand, at a dose of 2.4 mM/kg 3-AB and
NIC were equipotent in lowering MDA formation
(~24% increase above control, p<0.05).
NO is one of the metabolic products of STZ responsi-
ble for DNA strand breakage in pancreatic cells and for
the formation of the highly toxic peroxynitrite anion fol-
lowing interaction with reactive oxygen species (ROS)
[32]. In this study, STZ was found to cause a marked
increase in plasma NO (by ~450%, p<0.001 vs. control),
an effect that was lessened to different extents by a 2.4
mM/kg dose of 3-AB (143% increase), NIC (83%
increase) and TAU (5% decrease) relative to the control
value and which differed significantly from the value
with STZ alone (p<0.001) (Figure 7). Varying the dose
of TAU between 1.2 and 3.6 mM/kg had a very a small
dose-related increasing effect on the attenuating action
of both TAU and NIC on NO formation (Figure 7).
GSH is a biomolecule that functions as an antioxidant
by participating in the detoxification of electrophilic/oxi-
dizing xenobiotics, free radicals and peroxides [33].
Figure 6 Effects of 3-AB, NIC and TAU on plasma MDA of diabetic rats. Data are presented as mean ± S.E.M. for n = 6. Statistical
comparisons were significantly different at *P<0.05, **P<0.01 and ***P<0.001 vs. Control; at
++P<0.01 and
+++P<0.001 vs. STZ; and at °P<0.05 and
°°P<0.01 vs. 3-AB.
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Page 9 of 15During situations of oxidative stress, its intracellular
stores may become depleted by conjugating reactions,
by binding to susceptible cysteine residues in macromo-
lecules to form mixed disulfides, and by oxidation to its
disulfide form [33]. Hence its levels in tissues and in the
circulation may reflect the extent of the oxidative state.
In the present study, an acute treatment with STZ
caused a drastic (70%) reduction of the circulating GSH
(Figure 8). The administration of 3-AB, NIC or TAU as
a pretreatment to STZ led to significant protection
against the loss of GSH. Thus, at a dose of 2.4 mM/kg,
NIC (40% decrease) was somewhat better than 3-AB
(45% decrease) or TAU (48% decrease) in preserving the
levels of plasma GSH. While NIC was more protective
than TAU at doses ≤ 2.4 mM/kg, they provided equal
protection at a dose of 3.6 mM/kg (~33% decrease)
(Figure 8).
Discussion
In the present study, diabetes was induced by the intra-
peritoneal administration of STZ. This methylnitrosour-
eido derivative of D-glucose is well suited as
pharmacological tool for studying the effects of com-
pounds with PARP-1 inhibitory action and with poten-
tial for preventing the onset of type 1 diabetes in
experimental animals. Following its entry into pancreatic
b-cells, STZ will be toxic to cells because it depresses
the levels of NAD
+ and ATP as a result of several possi-
ble mechanisms. First, metabolism of its nitrosoureido
moiety can yield chemical species (methyl carbonium
ion, methyl radical) for alkylating DNA, inhibiting the
incorporation of precursors into DNA, and causing
DNA strand breaks [34,35]. There also evidence to indi-
cate that STZ can enhanced the production of NO, per-
oxynitrite and superoxide radical for widespread DNA
strand breakage [9,36-38]. Hence, and irrespective of
what causes DNA breakage, protracted activation of
PARP-1 to repair the damage and ensure pancreatic cell
survival will lead to b-cell dysfunction and culminate in
death by necrosis or apoptosis [9,37]. Additional factors
that contribute to the development of diabetes by STZ
are the decrease in the pancreatic GSH level with a cor-
responding increase in GSSG [35,39], and the inhibitory
action of the diabetogenic agent on the activity of islet
O-GlcNAcase, an enzyme that cleaves terminal b-O-
GlcNAc residues from modified nucleocytoplasmic
proteins acting as a glucose sensor [40,42].
The three compounds evaluated in the present study
are endowed with biological properties that are of bene-
fit in preventing or delaying the onset of type 1 diabetes
and to minimize the development of complications of
diabetes. In this context, while 3-AB and NIC have been
extensively studied for their PARP-1 inhibitory actions,
in the case of TAU such link appears lacking. Although
both 3-AB and NIC are examples of PARP inhibitors
that are presently considered to be of low potency when
compared to compounds designated as second- and
third-generation inhibitors, they are still used
Figure 7 Effects of 3-AB, NIC and TAU on plasma NO of diabetic rats. Data are presented as mean S.E.M. for n = 6. Statistical comparisons
were significantly different at *P<0.05 and ***P<0.001 vs. Control; at
+++P<0.001 vs. STZ; and at °P<0.05, °°P<0.01 and °°°P<0.001 vs. 3-AB.
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family of enzymes [42]. Among PARP inhibitors, NIC
remains a subject of clinical interest because of its pro-
ven antidiabetogenic effects on an experimental level,
ready availability, wide therapeutic index, and infrequent
reports of adverse effects when used in high doses on a
chronic basis [43]. More importantly, its lower potency
in comparison with 3-AB or newer benzamides guaran-
tees that some PARP activity will be left for the cell to
carry out normal DNA repairs [43].
In vitro testing of 3-AB, NIC and TAU for their
PARP-1 inhibitory activity indicated that 3-AB was
about 6.4-fold more potent than NIC and about 9.7-fold
more potent than TAU. The experimental IC50 values
for both 3-AB and NIC fall within the range of values
reported for these compounds in the scientific literature
[43,44]. With the help of molecular docking studies on
an X-ray crystallographic structure of PARP-1 in com-
plex with quinazolinedione, a PARP inhibitor, it was
possible to establish the binding characteristics of each
of the test compounds at the active site of PARP. While
t h em o r ep o t e n tP A R Pi n h i b i t o r s ,3 - A Ba n dN I C ,w e r e
found to enter into hydrogen bond associations with
Ser
904 and Gly
863 at the NI binding site of the active
site, the much weaker inhibitor, TAU, was forming
hydrogen bonds with Asp
766,A s p
770 and Arg
878 at the
AD site of the active site. Calculation of the correspond-
ing docking scores for each compound, which are
inversely related to the binding affinities, suggested
3-AB to be more tightly bound than NIC to the active
site of the enzyme than NIC, and TAU to be weakly
bound to PARP-1. In common with most PARP inhibi-
tors, the three compounds under evaluation are inhibit-
ing the enzyme in a competitive manner since they
block the binding of NAD
+ to the catalytic domain of
PARP-1 [44].
In addition to differences in inhibitory activity
imposed by their structural features [44], the action of
3-AB and NIC as inhibitors of PARP-1 inhibitors is also
found to depend on the time of their administration fol-
lowing a treatment with STZ. Indeed, a study in rats
evaluating 3-AB alongside NIC for their protective
actions against STZ-induced b-cell toxicity, verified that
protection by 3-AB remained when this compound was
given up to 120 min after STZ, the optimum being
45 min, but that it completely disappeared when given
240 min after STZ. In contrast, protection by NIC
required an administration earlier than 120 min. In
addition to normalizing the blood glucose and preser-
ving the plasma insulin levels, 3-AB was found to limit
the decrease in pancreatic insulin content in a dose-
dependent manner and to a greater extent than NIC
when given at the same mg/kg (75, 150, 300) doses [15].
Moreover, in the same study it was verified that islet
cells incubated in the presence of 3-AB or NIC were
able to retain their ability to secrete insulin in response
Figure 8 Effects of 3-AB, NIC and TAU on plasma GSH of diabetic rats. Data are presented as mean ± S.E.M. for n = 6. Statistical
comparisons were significantly different at **P<0.01 and ***P<0.001 vs. Control; at
+P<0.05,
++P<0.01 and
+++P<0.001 vs. STZ; and at °°P<0.01 vs.
3-AB.
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Page 11 of 15to a challenge with glucose, with the potency being
greater if the compound was added early in the incuba-
tion since it decreased as function of the time of addi-
tion after STZ.
A role of PARP activation in pancreatic islet cell
damage by STZ can be ascertained from the circulating
levels of both insulin and glucose, with the type of dia-
betes being a determined by the dose of STZ adminis-
tered [45]. In the present study, a 60 mg/kg dose of
STZ was found to induce type 2 diabetes since the levels
of immunoreactive insulin were still measurable at 24 hr
after STZ. To preclude the loss in inhibitory activity
observed when a PARP-1 inhibitor is given as a post-
treatment to STZ, all the treatment compounds were
administered 45 before STZ. When given at 2.4 mM/kg
dose prior to STZ, 3-ABC, NIC and TAU were able to
counteract the deleterious effect of STZ on the pancreas
as determined from the increases in plasma insulin
levels relative to STZ alone, and which were directly
proportional to their PARP-1-inhibitory potency. The
effect of both NIC and TAU in preserving the insulin-
secreting ability of the pancreas was enhanced by raising
their doses to 3.6 mM/kg, with TAU then becoming
equipotent to NIC. In parallel with the results for
plasma insulin, all the test compounds were found to
reduce the hyperglycemic response induced by STZ
when administered at a 2.4 mM/kg dose, with the effect
being directly proportional to the PARP-1 inhibitory
activity. At 1.2 mM/kg NIC was more potent than TAU
in reducing the plasma glucose due to STZ; but this dif-
ference was not observed when the two compounds
were administered at a dose of 3.6 mM/kg. Surprisingly,
at this particular dose the effects of TAU and NIC on
the plasma glucose became equal to that of a 2.4 mM/
kg dose of 3-AB.
In rodents, the induction of diabetes with a STZ is
known to lead to a hyperlipidemia characterized by ele-
vations in the circulating levels of total cholesterol, tri-
glycerides, very low density lipoprotein and low density
lipoprotein-cholesterol and by a decrease of high density
lipoprotein-cholesterol [36,39,47]. In the present study,
diabetes by STZ led to a marked increase in both the
plasma cholesterol and plasma triglyceride levels at
24 hr after STZ. At a 2.4 mM/kg dose, 3-AB and TAU,
but not NIC, were able to attenuate the elevations in
plasma lipids induced by STZ to a significant extent. In
this instance, both compounds attenuated the choles-
terol level to about the same extent and 3-AB was more
potent than TAU in lowering the triglycerides level seen
with STZ. Also, while a treatment with TAU at doses
ranging from 1.2 to 3.6 mM/kg produced a dose-related
decreasing effect on both plasma lipids, one with NIC at
the same doses had a negligible effect. These results
clearly suggest that the actions of 3-AB, NIC and TAU
in general and of NIC in particular are more dependent
on their intrinsic pharmacological actions than on their
PARP-1 inhibitory potencies.
Oxidative stress is a hallmark of STZ-induced diabetes
since this diabetogen can promote the formation of
ROS and NO in the pancreas [35,38,48] and other
major organs [49]. In b-cells, ROS and NO produced
from the metabolism of STZ itself and from other
sources, especially from the oxidation of glycated pro-
teins [50], can attack islet cell membranes to cause oxi-
dative damage and promote the release lipid
peroxidation products such as MDA and conjugated
dienes [23]. This process is compounded by the subse-
quent oxidative modifications to membranes lipids to
generate new free radicals, reactive aldehydes and lipid
peroxides, especially hydrogen peroxide, which are
thought to play an important role in the development of
diabetes and in the pathogenesis of diabetic complica-
tions since they can damage DNA and other cell com-
ponents [7,49,51]. Pancreatic b-cells are quite
susceptible to the effects of peroxides because of their
limited contents of catalase and peroxidase [7] and
because STZ also lowers the activities of antioxidant
enzymes such as glutathione peroxidase [52]. STZ-
mediated pancreatic b-cell damage may also be the
result of STZ attacking mitochondria to impair ATP
generation and increase ADP, thus providing mitochon-
drial xanthine oxidase with a substrate for the formation
of uric acid and superoxide anion radicals. Alternatively,
STZ can directly activate pancreatic xanthine oxidase to
enhance superoxide anion radical formation. In turn,
exposure of superoxide anion radicals to STZ can gener-
ate hydroxyl radicals [53].
The present study finds that all the test compounds
were able to lower the plasma levels of NO and MDA, a
secondary product of LPO, and to increase the plasma
GSH content relative to plasma levels from animals on
STZ alone. In all likelihood, these changes reflect the
intracellular status of those organs and tissues, particu-
larly erythrocytes, being affected by STZ-induced dia-
betes along with the activities of those intracellular
systems responsible for their formation [54], Further-
more, at a dose of 2.4 mM/kg TAU was the most potent
and 3-AB the least potent in attenuating MDA and NO
formation, and NIC was the most potent and 3-AB the
least potent in preventing the loss of GSH as a result of
a post-treatment with STZ. Without exceptions, the
protective effects of TAU and NIC were dose-related.
T h er e d u c t i o ni nL P Ob yt h e s ec o m p o u n d si sn o t
unexpected since they have all shown antioxidant prop-
erties in vivo, in vitro and ex vivo. Thus, 3-AB was
found to ameliorate peroxynitrite-induced cytotoxicity
[55], to effectively scavenge the hydroxyl radical and to
protect proteins against oxidation, but without been
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Page 12 of 15able to prevent FeCl2-induced LPO [56]. NIC can
contribute to the maintenance of the intracellular
GSH since it is a substrate for the de novo synthesis of
NAD
+.I nt u r n ,N A D
+ undergoes metabolic conversion
to NADP, which in its reduced form is an obligatory
cofactor for the redox cycling of GSH with its disulfide
form GSSG under the mediation of glutathione reduc-
tase [57]. Furthermore, since GSH is a cosubstrate for
glutathione peroxidase, it will play a protective role
against ROS generated during the oxidative metabolism
of glycated proteins formed as a result of chronic hyper-
glycemia [54,57]. In rats, feeding a diet supplemented
w i t hN I Cf o r4w e e k sp r i o rt oat r e a t m e n tw i t hS T Z
(40 mg/kg, i.v.) resulted in lower pancreatic TBARS
values than in animals consuming an unsupplemented
or NIC-deficient diet but without impacting on the liver
MDA values [58]. The same study found the liver con-
tents of GSH and vitamin E to be higher in animals on
the NIC-supplemented diet than in animals on the
unsupplemented and NIC-deficient diets. Furthermore,
in an in vitro study in which a rat brain was subjected
to cerebral ischemia and/or reperfusion, NIC was shown
to reduce neuronal ROS production, Ca
++ influx, apop-
tosis and cell injury in a dose-related manner [59].
In addition to its protective actions against STZ-
induced hyperglycemia and hypoinsulinemia [20], TAU
is reported to prevent glucose-induced membrane LPO
in cultured rat mesangial cells [60] and in the liver and
kidney of alloxan-treated rats [61] as inferred from the
levels of MDA, hydroperoxides and conjugated dienes
content; to attenuate the formation of chemiluminescent
products of LPO when egg yolk phosphatidylcholine
liposomes were incubated with 2,2’-azo-bis-(2-amidino-
propane) hydrochloride [AAPH], a water soluble oxygen
radical generator, possibly because of its sulfonate group
[62]; and to prevent hemolysis, but not LPO, when
intact canine erythrocytes were exposed to AAPH [63].
In mice, supplementation of the drinking water with
TAU reduced myocardial oxidative stress due to iron
overload and reversed the changes in MDA, hexanal, 4-
hydroxynonenal, GSH and GSSG production, and ele-
vated the GSH/GSSG ratio [64]. Feeding rats with TAU
(0.1%) as part of the drinking water was shown to pro-
tect the myocardium against free radical damage as a
result of in vitro electrolysis-induced ischemia/reperfu-
sion injury but without the ability to sequester superox-
ide anion radicals [65]. However, the apparent lack of
correlation between the beneficial antioxidant effects
manifested by TAU in diabetesa n do t h e rp a t h o l o g i c a l
conditions, and the inability of this sulfur compound to
directly scavenge free radicals (e.g., hydroxyl, superoxide
anion, peroxynitrite) or to react with H2O2 [63,66], has
cast doubts on an antioxidant action as the mechanism
whereby TAU protects the pancreas and other major
organs against injury by oxidative stress However, a
recent report has attempted to provide a unifying view
of this controversial issue [67 ] .I nb r i e f ,i ti sh y p o t h e -
sized that in diabetes the formation of ROS in the mito-
chondria of pancreatic islet cells exposed to high
glucose levels will negatively impact of the levels of pan-
creatic mitochondrial TAU. Since TAU is required for
the formation of mitochondrial TAU-conjugated tRNAs
which mediate the normal translation of mitochondrial-
encoded proteins, including protein components of the
respiratory chain, a deficiency of TAU will impair the
flow of electrons through the respiratory chain, promote
the accumulation of electron donors, reduce ATP pro-
duction, and divert electrons from the respiratory chain
to oxygen to generate superoxide anion. Hence, replen-
ishment of the mitochondrial stores of TAU will restore
respiratory chain function and ATP synthesis at the cost
of superoxide anion formation [67], and, more impor-
tantly, spare pancreatic cells from death.
Conclusions
The results of the present work indicate that TAU pos-
sesses PARP-1 inhibitory activity and that this activity is
rather weak when compared to classical PARP-1 inhibi-
tors such as 3-AB and NIC. Through molecular docking
analysis, TAU is found to bind to subsite of the active
s i t eo fP A R P - 1t h a ti sd i f f e r e n tf r o mt h a ts h a r e db y3 -
AB and NIC. When administered to rats at a 2.4 mM/
kg dose 45 min before a 60 mg/kg dose of STZ, 3-AB,
NIC and TAU demonstrated common attenuating
actions on the hyperglycemia, hypoinsulinemia and oxi-
dative stress induced by STZ, with 3-AB exhibiting the
greatest potency and TAU the least. However, at a dose
of 3.6 mM/kg the effects of TAU and NIC against STZ-
related alterations became either equal or greater than
t h o s eb ya2 . 4m M / k gd o s eo f3 - A B .I r r e s p e c t i v eo ft h e
dose used, TAU was the most protective among the
compounds tested against oxidative stress by STZ. On
the other hand, the lack of effect of NIC, a more potent
PARP-1 inhibitor than TAU on hyperlipidemia by STZ
suggests that PARP-1 inhibitory potency is not a reliable
predictor of the type and extent of the effect that a
PARP inhibitor may have on the plasma lipids asso-
ciated with diabetic hyperlipidemia.
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